Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.45 |
| ▸ | BRD4 | O60885 | 2/20 | 0.43 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.42 |
| ▸ | SLC10A2 | Q12908 | 1/20 | 0.41 |
| ▸ | NR1I3 | Q14994 | 3/20 | 0.40 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 3/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1115135 | 0.94 | CA12 (0.47) | IDO1BRD4CREBBPCA12CA1 | |
| SCHEMBL12394690 | 0.87 | MEN1 (0.41) | EPHX2IDO1MDM2 | |
| SCHEMBL22664849 | 0.84 | CA12 (0.45) | EPHX2IDO1BRD4CREBBPCA12 | |
| SCHEMBL2465280 | 0.84 | CA12 (0.45) | IDO1BRD4CREBBPCA12CA1 | |
| SCHEMBL14062472 | 0.82 | MAOA (0.54) | EPHX2 | |
| SCHEMBL3006400 | 0.81 | IDO1 (0.45) | EPHX2IDO1BRD4CREBBPCA12 | |
| SCHEMBL14872697 | 0.80 | CA12 (0.38) | BRD4CREBBPCA12CA1CA9 | |
| SCHEMBL27810168 | 0.80 | EPHX2 (0.60) | EPHX2IDO1BRD4CREBBPMDM2 | |
| SCHEMBL12370472 | 0.80 | EPHX2 (0.41) | EPHX2 | |
| SCHEMBL13500221 | 0.80 | RAB9A (0.58) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2714070-B1 | LONG-ACTING GLP-1/GLUCAGON RECEPTOR AGONISTS | OPKO BIOLOGICS LTD (IL) | 2024-03-20 | — | — | EP | disclosed |
| EP-3924369-A1 | LONG-ACTING GLP-2 ANALOGS | OPKO Biologics Ltd. (IL) | 2021-12-22 | — | — | EP | disclosed |
| CN-109096387-B | Pegylated OXM variants | 奥普科生物制品有限公司 | 2021-11-30 | — | — | CN | disclosed |
| CN-113710692-A | Long-acting GLP-2 analogs | OPKO生物科学有限公司 | 2021-11-26 | — | — | CN | disclosed |
| EP-3302571-B1 | PEGYLATED OXYNTOMODULIN VARIANTS | OPKO BIOLOGICS LTD (IL) | 2020-11-18 | — | — | EP | disclosed |
| EP-3302571-B1 | PEGYLATED OXYNTOMODULIN VARIANTS | OPKO BIOLOGICS LTD (IL) | 2020-11-18 | — | — | EP | disclosed |
| WO-2020165900-A1 | LONG-ACTING GLP-2 ANALOGS | OPKO BIOLOGICS LTD. (IL) | 2020-08-20 | — | — | WO | disclosed |
| US-20200254065-A1 | LONG-ACTING GLP-2 ANALOGS | OPKO BIOLOGICS LTD. (IL) | 2020-08-13 | — | — | US | disclosed |
| US-20200254065-A1 | LONG-ACTING GLP-2 ANALOGS | OPKO BIOLOGICS LTD. (IL) | 2020-08-13 | — | — | US | disclosed |
| US-20190160152-A1 | LONG-ACTING OXYNTOMODULIN FORMULATION AND METHODS OF PRODUCING AND ADMINISTERING SAME | OPKO BIOLOGICS LTD. (IL) | 2019-05-30 | — | — | US | disclosed |
| WO-2010014258-A2 | CONJUGATES HAVING A RELEASABLE LINKAGE | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2010-02-04 | — | — | WO | disclosed |
| US-7585837-B2 | derivatization of the drug with 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS) removable under mild basic conditions by attaching a protein or polymer carrier to derivatized drug molecule,such carrier serving for delivery of the drug | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2009-09-08 | — | — | US | disclosed |
| US-7585837-B2 | derivatization of the drug with 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS) removable under mild basic conditions by attaching a protein or polymer carrier to derivatized drug molecule,such carrier serving for delivery of the drug | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2009-09-08 | — | — | US | disclosed |
| US-7585837-B2 | derivatization of the drug with 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS) removable under mild basic conditions by attaching a protein or polymer carrier to derivatized drug molecule,such carrier serving for delivery of the drug | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2009-09-08 | — | — | US | disclosed |
| US-20090005574-A1 | reacting a 9-hydroxymethyl-2-amino fluorene with a silyl protecting reagent e.g. tert-butyldimethylsilyl chloride to form tert-butyldimethylsiloxy-9-methyl-2-aminofluorene, reacting intermediate with 3-maleimidopropionic acid; protecting; chemical intermediates for protein and peptide drugs | BAXTER INTERNATIONAL INC. (US) | 2009-01-01 | — | — | US | disclosed |
| US-20090005574-A1 | reacting a 9-hydroxymethyl-2-amino fluorene with a silyl protecting reagent e.g. tert-butyldimethylsilyl chloride to form tert-butyldimethylsiloxy-9-methyl-2-aminofluorene, reacting intermediate with 3-maleimidopropionic acid; protecting; chemical intermediates for protein and peptide drugs | BAXTER INTERNATIONAL INC. (US) | 2009-01-01 | — | — | US | disclosed |
| US-20090005574-A1 | reacting a 9-hydroxymethyl-2-amino fluorene with a silyl protecting reagent e.g. tert-butyldimethylsilyl chloride to form tert-butyldimethylsiloxy-9-methyl-2-aminofluorene, reacting intermediate with 3-maleimidopropionic acid; protecting; chemical intermediates for protein and peptide drugs | BAXTER INTERNATIONAL INC. (US) | 2009-01-01 | — | — | US | disclosed |
| WO-2009000523-A1 | METHOD FOR PREPARING FMOC-BASED HYDROLYSABLE LINKERS | BAXTER INTERNATIONAL INC. (US) | 2008-12-31 | — | — | WO | disclosed |
| WO-2009000523-A1 | METHOD FOR PREPARING FMOC-BASED HYDROLYSABLE LINKERS | BAXTER INTERNATIONAL INC. (US) | 2008-12-31 | — | — | WO | disclosed |
| US-20060171920-A1 | derivatization of the drug with 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS) removable under mild basic conditions by attaching a protein or polymer carrier to derivatized drug molecule,such carrier serving for delivery of the drug | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 2006-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060171920-A1 | derivatization of the drug with 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS) removable under mild basic conditions by attaching a protein or polymer carrier to derivatized drug molecule,such carrier serving for delivery of the drug | PTMS, FIBP, FLT3 | EPHX2 2383/4885IDO1 4610/4885BRD4 604/4885 |
| US-20090005574-A1 | reacting a 9-hydroxymethyl-2-amino fluorene with a silyl protecting reagent e.g. tert-butyldimethylsilyl chloride to form tert-butyldimethylsiloxy-9-methyl-2-aminofluorene, reacting intermediate with 3-maleimidopropionic acid; protecting; chemical intermediates for protein and peptide drugs | HGFAC, PTMS, PRMT9 | EPHX2 3437/4885IDO1 4529/4885BRD4 1194/4885 |
| US-20200254065-A1 | LONG-ACTING GLP-2 ANALOGS | GLP1R, GIPR, GCGR | EPHX2 2386/4885IDO1 4327/4885BRD4 2240/4885 |
| US-20190160152-A1 | LONG-ACTING OXYNTOMODULIN FORMULATION AND METHODS OF PRODUCING AND ADMINISTERING SAME | OGFR, VEGFA, OGFRL1 | EPHX2 1338/4885IDO1 4374/4885BRD4 4681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.